Dr. Vignali will discuss the biology of the inhibitory receptor LAG3, and its contribution to T cell exhaustion and immune regulation on CD8+ and CD4+ intratumoral T cells in mouse models of cancer and autoimmunity, and in a variety of human malignancies. He will also discuss the impact of LAG3 on regulatory T cell function. Given the considerable interest in inhibitory receptors in general, and LAG3 recently, as immunotherapeutic targets, he will also discuss how differential LAG3 expression could impact responsiveness to immunotherapy.

Disclosures

Vignali: Potenza Therapeutics: Consultancy, Equity Ownership, Membership on an entity's Board of Directors or advisory committees, Patents & Royalties: Licensed IP, Research Funding; Tizona Therapeutics: Consultancy, Equity Ownership, Membership on an entity's Board of Directors or advisory committees, Patents & Royalties, Research Funding; Oncorus: Consultancy, Equity Ownership, Membership on an entity's Board of Directors or advisory committees; Pieris: Membership on an entity's Board of Directors or advisory committees; FStar: Membership on an entity's Board of Directors or advisory committees; BMS: Equity Ownership; Merck: Equity Ownership; Crescendo: Consultancy; Intellia: Consultancy; MPM: Consultancy; Onkaido/Moderna: Consultancy; Servier: Consultancy.

Topics:
advisory committees, autoimmunity, cancer, cell cycle checkpoint, disclosure, equity, immunotherapy, mice, patents, regulatory t-lymphocytes

Author notes

*

Asterisk with author names denotes non-ASH members.

© 2017 by The American Society of Hematology
2017
Sign in via your Institution